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Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder estimated to affect greater than 1% of all adults over the age of 65 worldwide (Olanow and Tatton, 1999) . Although genetic mutations can cause PD, the vast majority of cases are idiopathic (Vila and Przedborski, 2004) and there is increasing evidence that exposure to environmental toxicants may play a significant role in PD (Sherer et al., 2002) . The key indication that environmental factors may play a role in PD came with the discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which caused an acute and permanent parkinsonian syndrome in intravenous drug users (Langston et al., 1983) . Since this discovery, MPTP has since been used to develop animal models of PD in several species and as a tool to understand the pathogenesis of PD and to test a variety of therapeutic interventions designed to prevent or reduce dopaminergic neurodegeneration (Dauer and Prezdborski, 2003) .
Despite intensive investigation, the molecular mechanism of MPTP has not been definitively demonstrated. MPP + , the active metabolite of MPTP, has been demonstrated to inhibit complex I of the mitochondrial electron transport chain, which was thought to be the mechanism by which MPTP induced parkinsonism (Nicklas et al., 1985) . However, the weak inhibitory ability of MPP + at complex I (Ramsay et al., 1991; Richardson et al., 2005) has led some to question the role of complex I inhibition in MPTP toxicity (Lotharius and O'Malley, 2000; Nakamura et al., 2000) . Unfortunately, complex I activity was not determined in these studies and the contribution of complex I in the toxicity of MPP + could not directly be (Trevor et al., 1987; Chen et al., 1995; Lotharius and O'Malley, 2000; Obata, 2002; Kooncumchoo et al., 2006; Obata, 2006) . Thus, the molecular mechanism of MPTP remains to be established.
Because the administration of MPTP to experimental animals is the most widely used model of PD, determination of the mechanism by which MPTP causes dopaminergic neurodegeneration may provide critical information on pathogenic process involved in PD.
Previously, we have demonstrated that the single-subunit NADH dehydrogenase of Saccharomyces cerevisiae (NDI1), can serve as a "replacement" for complex I in mammalian cells and restore electron transfer in cell devoid of mitochondrial DNA (Bai et al., 2001; Seo et al., 1998; and that NDI1 expression in neuroblastoma cells abolishes the toxicity of rotenone, a complex I inhibitor we have demonstrated to reproduce features of PD in rats (Betarbet et al., 2000; Sherer et al., 2003) . More recently, we have reported that NDI1 can be expressed in vivo using viral-mediated techniques and that unilateral expression of NDI1 partially protected against reduced tyrosine hydroxylase immunoreactivity resulting from an acute high dose regimen of MPTP (4x20 mg/kg over 1 day; Seo et al., 2006) . These findings suggested that NDI1 could provide some protection from MPTP neurotoxicity. However, the in vivo nature of our experiments prevented unequivocal identification of complex I as the target of MPTP. Additionally, the unilateral nature of our experiments did not allow us to determine whether NDI1-mediated neuroprotection would ameliorate the behavioral deficits observed following MPTP administration (Tillerson et al., 2003) . Here, we sought to definitively determine the role of complex I inhibition in the neurotoxicity produced by MPTP. 
Materials and Methods
Cell Culture. SK-N-MC neuroblastoma cells stably expressing NdI1 protein have been described previously (Sherer et al., 2003) . To demonstrate proper localization of NDI1 to the mitochondria, immunofluorescence microscopy was performed as described previously (Seo et al., 2000) . Briefly, cells were fixed and immunostained with a previously characterized affinitypurified rabbit antibody to NdI1 and an antibody to the mitochondrial F1-ATPase (Molecular Probes, Eugene, OR). Secondary antibodies were FITC-conjugated goat anti-rabbit for NdI1 and rhodamine red goat anti-mouse for F1-ATPase (Molecular Probes). For studies on MPP + toxicity, parental SK-N-MC or SK-N-MC cells stably expressing NDI1 (Sherer et al., 2003) were transfected with 4 µg of the dopamine transporter (DAT) in pCDNA 3.1 using Lipofectamine as described previously (Ramachandiran et al., in press ). Twenty-four hrs after transfection, cells were split into 24-well plates for determination of 3 H-MPP + uptake (Pifl et al., 1993) on the following day (48 hr after transfection). Briefly, cells were washed with 1 ml uptake buffer (4 mM Tris, 6.25 mM HEPES, 120 mM NaCl, 5 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgSO4, 5.6 mM D-glucose, and 0.5 mM ascorbic acid, pH 7.2) and incubated in 0.5 ml uptake buffer containing various concentrations (0.5 -40 µM) of cold MPP + and 0.25 µCi of 3 H-MPP + for 10 min at 37 o C. Non-specific uptake was determined in the presence of 10 µM nomifensine. Uptake was terminated by aspirating the uptake buffer and washing each well twice with 1 ml ice-cold uptake buffer. Cells were lysed by 1% sodium dodecyl sulfate and transferred into vials containing 5 ml of scintillation cocktail and radioactivity measured by liquid scintillation 6 counting. Uptake values were corrected for the amount of protein to account for variation in plating density and kinetic (K m and V max ) values were calculated by non-linear regression using GraphPad Prism 4.0. For studies on cell death, SK-N-MC cells stably expressing NDI1 were transfected with the DAT as described above. Cells were then incubated for 48 hr with 100 µM MPP + and cell death determined using Sytox green (Molecular Probes, Eugene, OR) with fluorescent detection as described previously (Sherer et al., 2003) . Following the last measurement, cells were incubated for 1 hr with 1% Triton and total fluorescence was determined to normalize for variation in plating density.
Animal Studies. Eight week old male C57BL/6j mice were obtained from an in-house breeding colony at the Scripps Research Institute. Mice received stereotaxic injections (anterior-posterior -3.3mm, medial-lateral +/-1.4mm, and dorso-ventral -3.9mm) of phosphate buffered saline vehicle (n = 14) or rAAV-NDI1 (n = 17), a recombinant adeno-associated serotype 2 virus carrying the NDI1 gene (1x10 11 IU/ml in phosphate buffered saline), bilaterally into the substantia nigra (Seo et al., 2004; . A total of 31 mice were shipped to Emory University at 4-5 months of age and quarantined for 3 months. Therefore, mice were 8 months of age at the time of experimentation, an age at which MPTP produces a sustained loss of dopaminergic terminals and cell bodies (Ali et al., 2003; Tillerson et al., 2003) . Mice were then assigned to one of 4 treatment groups: 1) vehicle-saline (n = 3); 2) vehicle-MPTP (2x15 mg/kg; n = 6); 3) NDI1-saline (n = 5); and 4) NDI1-MPTP (n = 12). The use of a higher number of animals in the NDI1-MPTP group was based on previous observations that the expression of NDI1 varies from animal to animal (Seo et al., 2006) . Animals underwent behavioral testing 7 days following MPTP treatment and were then sacrificed (Tillerson et al., 2002) . The brain was removed and divided at Neurochemical Determinations. Western blots were performed as previously described . Briefly, samples (20 µg) were subjected to SDS PAGE on 10% precast
NuPage gels (InVitrogen, Carlsbad, CA). Samples were electrophoretically transferred to a polyvinylidene difluoride membrane, and nonspecific sites were blocked in 7.5% nonfat dry milk in Tris-buffered saline (135 mM NaCl, 2.5 mM KCl, 50 mM Tris, and 0.1% Tween 20, pH 7.4).
Membranes were then incubated in a monoclonal antibody (Chemicon, Temecula, CA) HPLC analysis of catecholamines by electrochemical detection was performed as previously described (Richardson and Miller, 2004) . Briefly, dissected striata were sonicated in 0.1M perchloric acid containing 347 µM sodium bisulfite and 134 µM EDTA. Homogenates were centrifuged at 12,000 x g for 10 minutes at 4 o C, the supernatant removed, and filtered through a 0.22 micron filter by centrifugation at 12,000 x g for 10 minutes. The supernatants were then analyzed for levels of DA, DOPAC, and HVA. Levels were measured using HPLC with an eight-channel coulometric electrode array (ESA Coularray, Chelmsford, MA).
Quantification was made by reference to calibration curves made with individual monoamine standards.
Immunohistochemistry. Immunohistochemical analysis of tissue was performed as previously described by . Brains were serially sectioned at 25 µm on a freezing microtome. Tissue was rinsed in 1X TBS and incubated in 3% H 2 O 2 to quench endogenous peroxidases. Sections were blocked in 10% normal goat serum for 1 hour at room temperature before being incubated overnight with monoclonal mouse anti-TH (1:2,000) primary antibody.
The following day tissue was rinsed in 1X TBS then incubated for 1 hour in goat anti-mouse
(1:200) secondary antibody conjugated to biotin. Tissue was rinsed in 1X TBS and incubated for 9 microscope (Leica, Wetzlar, Germany). For final output, images were processed simultaneously and identically with Adobe Photoshop 7.0 software.
Behavioral Testing. Behavioral testing to determine the behavioral impact of MPTP administration was performed via the grid performance test as described previously (Tillerson et al., 2002, Tillerson and . Briefly, mice were lifted by their tail and slowly placed in the center of the horizontal grid and supported until they grabbed the grid with both their foreand hind-paws. The grid was then inverted and mice were videotaped while hanging upside down for 30 s. For analysis, videos were replayed using a recorder with slow motion and frameby-frame option by a person blinded to the treatment groups. Forepaw step length was measured as the number of grid squares/openings transversed. The average forepaw distance was calculated by summing the distances for each step then dividing by the total number of steps.
The number of unsuccessful forepaw steps divided by the total number of attempted forepaw steps was recorded as foot faults. An unsuccessful step was defined as an attempt to step or place the forepaw in which the paw clearly slipped from its destined position and had to be replaced on the grid by the animal.
Statistical analysis. All cell culture experiments represent 3-4 independent experiments performed in triplicate. The in vivo studies represent 3-12 independent animals for each treatment. Data were calculated as mean ± SEM and statistical analyses were performed on raw data. Differences between groups were determined by Student's t-test for analyses involving only two groups or by ANOVA followed by mean separation by the Student-Newman-Keuls (SNK) method for analyses involving more than two groups. Significance is reported at the level of p ≤ 0.05.
Results

MPP
+ toxicity is prevented by replacement of complex I with rotenone-insensitive NDI1.
In an earlier study, we demonstrated that stable expression of NDI1 in SK-N-MC neuroblastoma cells abolished rotenone toxicity, providing evidence of an obligatory role for complex I inhibition in rotenone toxicity (Sherer et al., 2003) . Here, we used these same cells to determine whether complex I is required for MPP + toxicity. NDI1 was properly incorporated into the mitochondria as evidenced by fluorescence micrographs demonstrating mitochondrial colocalization (far right panel) of NDI1 (left panel) and the F1-ATPase (middle panel) in SK-N-MC cells stably expressing NDI1 (Fig. 1A) . These cells were then transfected with the human dopamine transporter (DAT) to allow MPP + to gain access to the cells (Richardson et al., 2005) .
Following exposure to 100 µM MPP + for 48 hrs, 50-60% cell death was observed and this value was set as the maximum % of cell death of 100%. However, cell death was totally abolished in cells overexpressing NDI1 (Fig. 1B) , demonstrating the requirement of interaction of MPP + with complex I to cause toxicity in this system. This effect appears to be dependent on the presence of NDI1 rather than altered uptake of the toxin, as there were no differences in 3 H-MPP + uptake between NDI1 cells and SK-N-MC cells transfected with the DAT (Fig. 1C) .
Viral-mediated expression of NDI1 in vivo attenuates MPTP neurotoxicity.
To confirm our in vitro findings, we employed a bilateral injection to deliver NDI1 in a viral vector to the brain, which we have previously demonstrated to confer expression in dopaminergic terminals in the striatum (Seo et al., 2004) . NDI1 expression did not alter basal dopamine levels when compared to animals who received vehicle at the time of surgery (data not shown) and these values were combined to form the control group. Administration of a moderate dose of MPTP (2x15 mg/kg) resulted in an 84% decrease of striatal dopamine 7 days after administration in animals receiving vehicle at surgery. This effect was greatly attenuated in mice expressing NDI1, with only a 48% decrease of striatal dopamine observed ( Fig. 2A) . There was a wide range of variance observed as some animals (n=3) showed a small amount of protection (74% decrease of striatal dopamine), some (n = 6) that showed a moderate level of protection (60% decrease of striatal dopamine), and some (n = 3) that showed total protection as evidenced by no significant loss of dopamine. These results are consistent with variation in expression of NDI1 between animals and our previous observation that not all dopamine neurons express NDI1 after injection of rAAV-NDI1 (Seo et al., 2006) . To confirm this variation, we attempted to perform immunohistochemical analysis of NDI1 expression in each individual animal.
Unfortunately, technical limitations of the NDI1 antibody prevented successful quantification of NDI1 levels. However, overall significant neuroprotection was observed, suggesting that viralmediated expression of NDI1 is a plausible means for providing neuroprotection against MPTP.
In addition to measures of striatal dopamine depletion, we also assessed neurochemical markers in the striatum of these same animals to determine the degree of dopaminergic damage (Tillerson et al., 2002) . Similar to the effects observed on striatal dopamine depletion, NDI1
expression provided a significant level of neuroprotection against the loss of DAT (Fig. 2B ), tyrosine hydroxylase (TH; Fig. 2C ), and vesicular monoamine transporter 2 (VMAT2; Fig. 2D) protein levels as determined by immunoblotting. MPTP treatment caused a 70% reduction of DAT in animals receiving vehicle at surgery. This was significantly attenuated by NDI1, with only a 41% loss observed in animals receiving NDI1 at surgery. A similar protective effect was 12 observed when we measured levels of TH and VMAT2. MPTP caused a 63% and 45% decrease in TH and VMAT2 levels in vehicle injected mice. However, TH and VMAT2 levels were only decreased by 32% and 23% in NDI1 injected mice. As can be seen in the representative western blots (Fig. 2E) , the neuroprotection observed ranged from partial to complete. NDI1 expression did not alter DAT or VMAT2 levels as compared to animals that received vehicle at surgery (data not shown), suggesting that the neuroprotective effect of NDI1 against MPTP toxicity is likely not the result of altered uptake of or enhanced sequestration of MPP + . No significant effect of NDI1 expression was observed on TH protein levels. We observed a similar range of neuroprotection when TH immunoreactivity in the striatum was assessed by immunohistochemistry ( Fig. 3A-F) . Finally, we performed immunohistochemical staining of TH in the cell bodies in the substantia nigra pars compacta and found a similar range of neuroprotection ( Fig. 3G-L) . Although immunohistochemical staining as performed here is qualitative, these data support the ability of NDI1 to protect both the dopaminergic terminals and cell bodies from MPTP-induced neurodegeneration.
Viral-mediated expression of NDI1 in vivo attenuates glial and microglial activation.
Astrogliosis and microgliosis have been used extensively as markers of MPTP-induced neurotoxicity (O'Callaghan et al., 1990; Francis et al., 1995) . Here, we determined GFAP levels as an indicator of astrogliosis (O'Callaghan et al., 1990) and Glut5 levels as an indicator of microgliosis (Payne et al., 1997) to determine whether NDI1 expression in vivo would attenuate the glial response in response to MPTP administration. Basal levels of GFAP and Glut5 as assessed by western blot were not significantly different between animals administered vehicle and those administered NDI1 and were combined to form a pooled control group. MPTP by guest on November 7, 2016
http://toxsci.oxfordjournals.org/ Downloaded from treatment increased GFAP levels by 42% in animals receiving vehicle as the time of surgery, whereas those receiving NDI1 and subsequent MPTP treatment exhibited only a 17% increase in GFAP levels (Fig. 4A) . A similar protective effect was observed for microglial proliferation as assessed by determining Glut5 levels. MPTP treatment increased Glut5 levels by 34% in animals receiving vehicle at surgery. This increase was attenuated in animals receiving NDI1, who only exhibited a 15% increase in Glut5 levels (Fig. 4B) . As with the other measures of MPTP-induced neurotoxicity, there was a range of neuroprotection observed with these markers (Fig. 4C ).
However, NDI1 treatment provided a significant overall level of neuroprotection.
Viral-mediated expression of NDI1 in vivo abolishes MPTP-induced behavioral deficits.
The loss of motor control and associated behavioral dysfunction is the most debilitating symptom of PD. In previous studies, we established the grid performance test as a sensitive indicator of dopamine-associated behavioral impairment in the MPTP mouse model of PD (Tillerson et al., 2002; Tillerson and Miller, 2003) . Here we sought to determine whether the amelioration of dopaminergic damage by NDI1 would result in prevention of MPTP-induced behavioral deficits. Administration of MPTP to animals given vehicle during surgery reduced forepaw step length on the grid to 50% of control values (Fig.5 ) while animals expressing NDI1
did not exhibit a significant reduction in forepaw step length. In contrast to the variation in protective effect observed at the neurochemical level, NDI1 expressing animals were totally resistant to the behavioral deficit caused by MPTP neurotoxicity, suggesting that even a small amount of neuroprotection is sufficient to prevent behavioral impairment. NDI1 expression also decreased the percentage of foot faults in MPTP-treated animals, but this effect did not quite reach statistical significance (p = 0.0579; data not shown). 
Discussion
There is accumulating evidence suggesting that oxidative damage to and dysfunction of complex I of the mitochondrial electron transport chain may be involved in PD pathogenesis (Beal, 2002; Dawson and Dawson, 2003; Greenamyre et al., 2001) . The observation of reduced complex I activity in PD patients provided some of the first clinical evidence of the potential involvement of complex I dysfunction in PD (Mizuno et al., 1989; Parker et al., 1989; Schapira et al., 1989) . Most recently, Jin and colleagues reported 3-fold decreases of two subunits of complex I in the substantia nigra of PD patients compared to age-matched controls using a proteomic approach (Jin et al., 2006) . Furthermore, the development of the rotenone rat model of PD provided direct experimental evidence that complex I inhibition alone is sufficient to induce a parkinsonian syndrome (Betarbet et al., 2000) . Although PD is not typically considered a mitochondrial disease, these studies cited above and recent work demonstrating that genes linked to PD affect mitochondrial function or localize to the mitochondria suggest that mitochondrial dysfunction, especially at complex I, may play a larger role in the development of PD than previously realized (Schapira, 2006) .
In 1983, astute epidemiological and clinical observation by Langston and colleagues led to the identification of MPTP as a compound capable of causing an acute permanent parkinsonian syndrome that was virtually indistinguishable from PD in a group of drug users in California (Langston et al., 1983) . Since this time, almost 4000 articles have been published on MPTP according to PubMed. However, the critical issue of how MPTP exerts its toxicity on dopamine neurons has remained a topic of debate. It has been argued that complex I inhibition does not completely explain the neurotoxicity of MPTP (Lotharius and O'Malley, 2000; Nakamura et al., 2000; Obata, 2002) . Previously, we have demonstrated that MPP + binds to the same site on complex I as rotenone (Richardson et al., 2005) and NDI1-expressing cells are resistant to rotenone toxicity because of the lack of this binding site (Sherer et al., 2003) . vivo, such as microglial activation or excitoxicity (Beal, 1998; Wu et al., 2002) , these findings suggest that complex I is likely the primary molecular site of action and initiator of MPP + neurotoxicity. An alternate hypothesis for MPTP toxicity has proposed that displacement of dopamine from synaptic vesicles (Lotharius and O'Malley, 2000; Obata, 2002) and resultant oxidative damage may be largely responsible for MPTP toxicity. However, a recent study employing genetic and pharmacological depletion of dopamine in mice revealed that the absence of dopamine did not exacerbate MPTP toxicity (Hasbani et al., 2005) , suggesting that dopamine displacement does not play a primary role in MPTP toxicity and reinforcing findings that complex I is the primary molecular target of MPTP.
Having established that NDI1 overexpression prevented MPP + toxicity in vitro, we next sought to determine whether bilateral injection of an adeno-associated virus carrying the NDI1 gene into the substantia nigra could prevent the neurotoxicity of MPTP. Recently, we utilized unilateral administration of NDI1 to test the ability of NDI1 to protect against high dose MPTP toxicity and found some degree of neuroprotection for all but 3 of the 13 mice examined (Seo et al., 2006) . Although the use of a unilateral injection paradigm in our initial study allowed the untreated side was able to serve as an internal control, this may not be the most optimal paradigm for assessing the dopaminergic toxicity of MPTP. First, there appears to natural imbalance in the dopamine system between the left and right side of the caudate putamen. Indeed, unilateral toxin lesions in experimental animals can result in sprouting of dopaminergic projections on both sides, which may affect the outcomes measured (Blanchard et al., 1996) . Here, we used bilateral injections of NDI1 and systemic MPTP to more closely mimic the clinical condition observed in PD. Bilateral injection of NDI1 into the substantia nigra did indeed provide significant protection against striatal dopamine depletion following MPTP administration (48% decrease in NDI1
expressing animals and 84% in non-NDI1 injected animals), similar to that observed with unilateral injection. Because we have previously observed that there appears to be variance in the level of transgene expression between individual animals (Seo et al., 2006) , it is possible that there is variance in the degree of neuroprotection between individual animals. Indeed, we found that out of the 12 animals injected with NDI1 and MPTP, there was a wide range of protection observed (10%-100%). These results were corroborated by western blots of DAT, TH, and VMAT2 in these same animals, which we have previously shown to be excellent indicators of MPTP-induced dopaminergic damage (Tillerson et al., 2002) . DAT levels were not significantly different between NDI1 expressing animals and those not expressing NDI1, suggesting that altered uptake of MPP + is not likely to have influenced the results similar to what we observed in vitro. We also observed qualitatively similar results when we analyzed dopaminergic damage by immunohistochemical methods for TH in the dopaminergic cell bodies of the substantia nigra and terminals in the striatum. Finally, a similar degree of neuroprotection was observed when we assessed the degree of astrogliosis and microgliosis, which have been shown to be excellent indicators of MPTP-induced neurotoxicity and known to be increased in PD brain. It should be noted that we assessed astrogliosis and microgliosis at 7 days following injection, which is not the peak of activation of these markers (Francis et al., 1995) . Therefore, we cannot rule out that similar degrees of glial activation may occur between vehicle and NDI1 injected animals treated with MPTP at the time of peak effect. Nonetheless, the totality of our assessments clearly demonstrates a significant protective effect of NDI1 against MPTP neurotoxicity. Although we did observed variance in the protective effect of NDI1, recent advances in viral and non-viral methods for introducing transgenes into the brain may provide an avenue for achieving increased and more consistent transgene expression allowing for increased neuroprotection in future experiments (de Lima et al., 2005) .
In PD, there is evidence that neurodegeneration begins long before patients are diagnosed
and that the behavioral symptoms that are characteristic of PD and the most devastating part of the disease process do not fully manifest until there is greater than 80% loss of striatal dopamine (Koller, 1992) . We have previously developed sensitive behavioral tests in MPTP-treated mice that correlate highly with loss of striatal dopamine and are able to detect behavioral dysfunction when there is less than 80% dopamine depletion (Tillerson et al., 2002; Tillerson and Miller, 2003) . Here, we observed total prevention of MPTP-induced behavioral deficits in NDI1 expressing mice. Significant protection was observed even in the animals that were only marginally protected from the neurochemical deficits caused by MPTP. These data suggest that even a small level of neuroprotection is sufficient to ameliorate behavioral deficits in an animal model of PD. Taken in concert, our data provide support for the inhibition of complex I as a major contributor to the dopaminergic degeneration and behavioral deficits observed in animals treated with MPTP. Mice were treated as described in Fig. 2 
and western blots for (A) GFAP and (B)
Glut5 were used to determine the level of glial and microglial activation, respectively.
There were no significant differences between vehicle or NDI1 injected animals and the data from these groups were collapsed to form the control group. Results represent mean ± SEM. *** indicates significantly different from control (p ≤ 0.001)
by ANOVA followed by means separation by SNK. ** indicates significantly different from vehicle mice administered MPTP (p ≤ 0.01). (C) Representative western blots of GFAP, Glut5, and β-actin, which was used to ensure equal protein loading. Mice were treated as described in Fig. 2 . One week after MPTP administration, mice were tested on the grid test for behavioral deficits as determined by forepaw step distance. MPTP administration significantly reduced forepaw step distance in vehicle treated animals (p ≤ 0.05). This behavioral deficit was prevented in NDI1 expressing animals as there was no significant difference between control animals and NDI1 animals administered MPTP. 
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